Axsome Therapeutics (AXSM) Prepaid Assets (2015 - 2026)
Axsome Therapeutics (AXSM) posted Prepaid Assets of $23.5 million for Q1 2026, up 72.32% sequentially from $13.7 million in Q4 2025, and up 46.95% YoY from $16.0 million in Q1 2025.
Analysis
Axsome Therapeutics (AXSM) Prepaid Assets (2015 - 2026) Analysis & Trends
Axsome Therapeutics has reported Prepaid Assets for 12 years, with the latest figure at $23.5 million in Q1 2026.
- Quarterly Prepaid Assets rose 46.95% year-over-year to $23.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.5 million (up 46.95% YoY) and the FY2025 annual result came in at $13.7 million, up 13.97% from the prior year.
- Prepaid Assets grew to $23.5 million in Q1 2026 per AXSM's latest filing, from $13.7 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $23.5 million in Q1 2026 and troughed at $2.1 million in Q1 2022.
- A 5-year average of $10.4 million and a median of $11.8 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2025: Prepaid Assets surged 6040.97% in 2022, then advanced 13.97% in 2025.
- Over 5 years, Prepaid Assets stood at $2.8 million in 2022, then jumped by 191.8% to $8.1 million in 2023, then surged by 47.6% to $12.0 million in 2024, then increased by 13.97% to $13.7 million in 2025, then soared by 72.32% to $23.5 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $23.5 million, $13.7 million, and $19.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.38 Mn |
| Mar 31, 2026 | 23.52 Mn |
| Dec 31, 2025 | 13.65 Mn |
| Sep 30, 2025 | 19.79 Mn |
| Jun 30, 2025 | 16.34 Mn |
| Mar 31, 2025 | 16.01 Mn |
| Dec 31, 2024 | 11.98 Mn |
| Sep 30, 2024 | 13.41 Mn |
| Jun 30, 2024 | 11.81 Mn |
| Mar 31, 2024 | 12.03 Mn |
| Dec 31, 2023 | 8.12 Mn |
| Sep 30, 2023 | 6.80 Mn |
| Jun 30, 2023 | 5.91 Mn |
| Mar 31, 2023 | 5.20 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 4.09 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Dec 31, 2021 | 45,286.00 |
| Sep 30, 2021 | 401,302.00 |